Clinical Trial Update: Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating high-dose rifampicin to shorten treatment for drug-sensitive pulmonary tuberculosis (Hi-DoRi-3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis
• Tuberculosis of the Lung

Drugs mentioned

• Rifampicin (high-dose formulation for Hi-DoRi-3 therapy) (rifampicin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Tuberculosis, Pulmonary | Phase 3 | Status: NOT_YET_RECRUITING